menu search

NBIX / Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch

Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch. Read More
Posted: Apr 24 2023, 19:30
Author Name: Seeking Alpha
Views: 112229

NBIX News  

Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 31, 2023

Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Todd Tushla - Vice Presi more_horizontal

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

By Zacks Investment Research
October 31, 2023

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compa more_horizontal

Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success

By Seeking Alpha
October 11, 2023

Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success

Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult more_horizontal

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

By Zacks Investment Research
October 3, 2023

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market. more_horizontal

Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It

By Seeking Alpha
August 25, 2023

Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It

Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinec more_horizontal

Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatment

By Market Watch
August 21, 2023

Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatment

Neurocrine Biosciences Inc. NBIX, +2.55% said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary more_horizontal

Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say

By Zacks Investment Research
August 1, 2023

Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth consid more_horizontal

Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch

By Seeking Alpha
April 24, 2023

Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch

Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch. more_horizontal


Search within

Pages Search Results: